The stock of Trevena Inc (NASDAQ:TRVN) is a huge mover today! About 434,083 shares traded hands or 35.46% up from the average. Trevena Inc (NASDAQ:TRVN) has declined 49.16% since April 8, 2016 and is downtrending. It has underperformed by 54.80% the S&P500.
The move comes after 5 months positive chart setup for the $304.79 million company. It was reported on Nov, 10 by Barchart.com. We have $14.09 PT which if reached, will make NASDAQ:TRVN worth $518.14 million more.
Trevena Inc (NASDAQ:TRVN) Ratings Coverage
Out of 7 analysts covering Trevena Inc (NASDAQ:TRVN), 6 rate it a “Buy”, 0 “Sell”, while 1 “Hold”. This means 86% are positive. Trevena Inc has been the topic of 10 analyst reports since August 3, 2015 according to StockzIntelligence Inc. WallachBeth Capital initiated the shares of TRVN in a report on Wednesday, March 2 with “Buy” rating. The stock of Trevena Inc (NASDAQ:TRVN) earned “Equal-Weight” rating by Barclays Capital on Tuesday, September 1. The rating was initiated by FBR Capital with “Outperform” on Tuesday, March 29. The stock of Trevena Inc (NASDAQ:TRVN) earned “Outperform” rating by Cowen & Co on Tuesday, September 1. The stock has “Market Outperform” rating given by JMP Securities on Wednesday, March 9. The firm has “Buy” rating by Needham given on Tuesday, August 11. As per Monday, August 3, the company rating was initiated by Brean Capital. The stock of Trevena Inc (NASDAQ:TRVN) has “Buy” rating given on Wednesday, September 2 by JMP Securities.
According to Zacks Investment Research, “Trevena, Inc. is a biopharmaceutical company. It focuses on discovering and developing therapeutics for G protein coupled receptors. The Company’s product pipeline includes TRV027, TRV130, TRV734 and Delta opioid biased ligand which are in different clinical phases. Trevena, Inc. is based in King of Prussia, Pennsylvania.”
More news for Trevena Inc (NASDAQ:TRVN) were recently published by: Businesswire.com, which released: “Trevena, Inc. Receives FDA Breakthrough Therapy Designation for Oliceridine …” on February 22, 2016. Businesswire.com‘s article titled: “Trevena, Inc. Announces Proposed Underwritten Offering of Common Stock” and published on September 10, 2015 is yet another important article.
TRVN Company Profile
Trevena Inc., incorporated on November 9, 2007, is a clinical-stage biopharmaceutical company. The Firm discovers, develops and intends to commercialize therapeutics that use an approach to target G protein coupled receptors (GPCRs). Using its product platform, the Company has identified and advanced three differentiated product candidates: Oliceridine (TRV130), TRV027 and TRV250. In addition to these three product candidates, it has identified and has completed the Phase I program for TRV734, an orally administered clinical compound expected to be used for first-line treatment of moderate to severe acute and chronic pain.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.